Srinivas Akkaraju - May 24, 2023 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC. (ICPT)

Role
Director
Signature
/s/ Rocco Venezia, as attorney-in-fact
Stock symbol
ICPT
Transactions as of
May 24, 2023
Transactions value $
$0
Form type
4
Date filed
5/25/2023, 08:37 PM
Previous filing
Feb 16, 2023
Next filing
May 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICPT Common Stock Award $0 +8.11K +21.41% $0.00 46K May 24, 2023 Direct F1
holding ICPT Common Stock 641K May 24, 2023 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICPT Option to Purchase Common Stock Award $0 +12.5K $0.00 12.5K May 24, 2023 Common Stock 12.5K $9.17 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders.
F2 Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.
F3 All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders.